Premium
The Role of OPG/TRAIL Complex in Multiple Myeloma
Author(s) -
BRUNETTI GIACOMINA,
COLUCCI SILVIA,
RIZZI RITA,
MORI GIORGIO,
COLAIANNI GRAZIANA,
ORANGER ANGELA,
ZALLONE ALBERTA,
LISO VINCENZO,
GRANO MARIA
Publication year - 2006
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1346.049
Subject(s) - rankl , osteoprotegerin , peripheral blood mononuclear cell , osteoclast , chemistry , receptor , in vitro , macrophage , medicine , multiple myeloma , endocrinology , cancer research , microbiology and biotechnology , immunology , biology , activator (genetics) , biochemistry
Multiple myeloma (MM) is often associated with an increased osteoclast (OC) activity. Using an in vitro osteoclastogenesis model consisting of MM unstimulated and unfractionated peripheral blood mononuclear cells (PBMCs), we showed that T cells support OC formation and survival. Differently, in T cell‐depleted MM PBMC cultures, exogenous macrophage‐colony stimulating factor (M‐CSF) and receptor activated of nuclear factor‐κB ligand (RANKL) were necessary for osteoclastogenesis. We found RANKL, OPG, and TRAIL overexpression by fresh MM T cells. Despite high osteoprotegerin (OPG) levels, the persistence of osteoclastogenesis can be related to the formation of the OPG/TRAIL complex. Our results highlight that MM T cells support OC formation and survival, possibly involving OPG/TRAIL interaction.